Abstract
In this study, synthesis, characterization and carbonic anhydrase I, and II isoenzymes (hCA I and II) acetylcholinesterase (AChE), enzymes and α-glycosidase (α-Gly) inhibition effects of some nitrogen, phosphorus, selenium and sulfur-containing heterocyclic compounds were achieved.
[Display omitted]
•The synthesis of N, P, Se and S-containing heterocyclic compounds was achieved.•They have been characterized by 1H NMR, 13C NMR, 31P NMR, 77Se NMR and IR analysis.•Their inhibition effects determined on hCA I and hCA II isoenzymes.•Their inhibition effects demonstrated against α-glycosidase and acetylcholinesterase enzymes.
Sulfur-containing pyrroles (1–3), tris(2-pyridyl)phosphine(selenide) sulfide (4–5) and 4-benzyl-6-(thiophen-2-yl)pyrimidin-2-amine (6) were synthesized and characterized by elemental analysis, IR and NMR spectra. In this study, the synthesized compounds of nitrogen, phosphorus, selenium and sulfur-containing heterocyclic compounds (1–6) were evaluated against the human erythrocyte carbonic anhydrase I, and II isoenzymes, acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α-glycosidase enzymes. The synthesized heterocyclic compounds showed IC50 values in range of 33.32–60.79 nM against hCA I, and 37.05–66.64 nM against hCA II closely associated with various physiological and pathological processes. On the other hand, IC50 values were found in range of 13.13–22.21 nM against AChE, 0.54–31.22 nM against BChE, and 13.51–26.55 nM against α-glycosidase as a hydrolytic enzyme. As a result, nitrogen, phosphorus, selenium and sulfur-containing heterocyclic compounds (1–6) demonstrated potent inhibition profiles against indicated metabolic enzymes. Therefore, we believe that these results may contribute to the development of new drugs particularly in the treatment of some global disorders including glaucoma, Alzheimer’s disease and diabetes.